NZ598801A - Use of the sparc microenvironment signature in the treatment of cancer - Google Patents

Use of the sparc microenvironment signature in the treatment of cancer

Info

Publication number
NZ598801A
NZ598801A NZ598801A NZ59880110A NZ598801A NZ 598801 A NZ598801 A NZ 598801A NZ 598801 A NZ598801 A NZ 598801A NZ 59880110 A NZ59880110 A NZ 59880110A NZ 598801 A NZ598801 A NZ 598801A
Authority
NZ
New Zealand
Prior art keywords
tumor
sparc
antibody
immunostaining
histologic sections
Prior art date
Application number
NZ598801A
Other languages
English (en)
Inventor
Vuong Trieu
Neil Desai
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of NZ598801A publication Critical patent/NZ598801A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nanotechnology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NZ598801A 2009-09-18 2010-09-20 Use of the sparc microenvironment signature in the treatment of cancer NZ598801A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27696909P 2009-09-18 2009-09-18
PCT/US2010/049545 WO2011035274A1 (en) 2009-09-18 2010-09-20 Use of the sparc microenvironment signature in the treatment of cancer

Publications (1)

Publication Number Publication Date
NZ598801A true NZ598801A (en) 2014-07-25

Family

ID=43759058

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ598801A NZ598801A (en) 2009-09-18 2010-09-20 Use of the sparc microenvironment signature in the treatment of cancer

Country Status (13)

Country Link
US (1) US20120245089A1 (cg-RX-API-DMAC7.html)
EP (1) EP2478362B1 (cg-RX-API-DMAC7.html)
JP (1) JP2013505268A (cg-RX-API-DMAC7.html)
KR (1) KR20120092597A (cg-RX-API-DMAC7.html)
CN (1) CN102576016A (cg-RX-API-DMAC7.html)
AU (1) AU2010295324B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012008316A2 (cg-RX-API-DMAC7.html)
CA (1) CA2774550A1 (cg-RX-API-DMAC7.html)
IL (1) IL218642A0 (cg-RX-API-DMAC7.html)
MX (1) MX2012003287A (cg-RX-API-DMAC7.html)
NZ (1) NZ598801A (cg-RX-API-DMAC7.html)
WO (1) WO2011035274A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201202657B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383358B2 (en) * 2009-05-28 2013-02-26 Abraxis Bioscience, Llc Use of 2 anti-SPARC antibodies to predict response to melanoma chemotherapy
AU2011261240A1 (en) * 2010-06-03 2013-01-10 Abraxis Bioscience, Llc Use of the SPARC microenvironment signature in the treatment of cancer
EP3539080B1 (en) * 2016-11-10 2022-03-23 F. Hoffmann-La Roche AG Distance-based tumor classification

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5003621A (en) 1989-11-02 1991-03-26 Motorola, Inc. Direct conversion FM receiver
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO2004085621A2 (en) * 2003-03-20 2004-10-07 Dana-Farber Cancer Institute, Inc. Gene expression in breast cancer
ATE511550T1 (de) * 2003-07-17 2011-06-15 Pacific Edge Biotechnology Ltd Marker zum nachweis von magenkrebs
JP4682152B2 (ja) * 2003-12-31 2011-05-11 ザ・ペン・ステート・リサーチ・ファンデーション 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法
AU2006249235B2 (en) * 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
GB0417740D0 (en) * 2004-08-10 2004-09-08 Uc3 Methods and kit for the prognosis of breast cancer
AU2005297303B2 (en) * 2004-10-19 2011-11-10 Lsip, Llc Novel diagnostic kit for malignant melanoma
CN103169729A (zh) * 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
WO2006112930A2 (en) * 2005-02-18 2006-10-26 Abraxis Bioscience, Inc. Q3 sparc deletion mutant and uses thereof
RU2451521C2 (ru) * 2006-06-16 2012-05-27 Онкотерапи Сайенс, Инк. Sparc-производные антигенные пептиды отторжения опухоли и лекарственные средства, содержащие их
US9675578B2 (en) * 2006-12-14 2017-06-13 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
AU2008226283A1 (en) * 2007-03-09 2008-09-18 The University Of British Columbia Assessing chemotherapy resistance of colorectal tumors by determining sparc hypermethylation
CN101678078B (zh) * 2007-04-13 2014-12-10 阿布拉西斯生物科学公司 Sparc及其使用方法
AU2008260447B2 (en) * 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer

Also Published As

Publication number Publication date
AU2010295324A1 (en) 2012-04-05
US20120245089A1 (en) 2012-09-27
BR112012008316A2 (pt) 2017-06-06
WO2011035274A1 (en) 2011-03-24
CN102576016A (zh) 2012-07-11
IL218642A0 (en) 2012-05-31
AU2010295324B2 (en) 2015-04-30
JP2013505268A (ja) 2013-02-14
MX2012003287A (es) 2012-08-03
EP2478362B1 (en) 2016-05-11
ZA201202657B (en) 2013-09-25
EP2478362A1 (en) 2012-07-25
CA2774550A1 (en) 2011-03-24
EP2478362A4 (en) 2013-09-11
KR20120092597A (ko) 2012-08-21

Similar Documents

Publication Publication Date Title
AR084723A1 (es) microARN (miARN) COMO BIOMARCADOR PARA LA IDENTIFICACION DEL CANCER COLORRECTAL FAMILIAR Y NO FAMILIAR
Yu et al. Downregulation of miR‐29 contributes to cisplatin resistance of ovarian cancer cells
WO2011112903A3 (en) Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients
NZ607282A (en) Method for using gene expression to determine prognosis of prostate cancer
AR080505A1 (es) Metodos para el tratamiento de linfoma no hodkin usando lenalidomida, y bimarcadores genicos y proteicos como indicadores
WO2012054747A3 (en) Methods and compositions for treating tumors using myeloid derived suppressor cells
WO2013124815A3 (en) Mesenchymal stem cells for in vitro modeling and cell-based therapy of human diseases and banks thereof
PH12014502548A1 (en) Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity, and said ligands
WO2012044696A3 (en) Prediction of clinical outcome in hematological malignancies using a self-renewal expression signature
WO2008115750A3 (en) Compositions and methods for the treatment of cancer
Balvan et al. Oxidative stress resistance in metastatic prostate cancer: renewal by self-eating
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
NZ609567A (en) Markers of endothelial progenitor cells and uses thereof
WO2012028961A3 (en) Compositions and methods for treating friedreich's ataxia with interferon gamma
WO2013177011A3 (en) In vitro tumor in dish kit and method
MX2013012648A (es) Metodo para determinar hipoxia clinicamente relevante en cancer.
WO2011149529A3 (en) Cell-based preparations for wound management
WO2012003493A3 (en) Protein kinase ck2 gene mutations, amplifications and polymorphisms in human cancers and methods of use
Tong et al. Prognostic Significance of HMGA1 in Hepatocellular Carcinoma: Implications for Tumor Progression and Targeted Therapy
CN202420940U (zh) 一种免疫组织化学用载玻片
RU2009121722A (ru) Способ диагностики опухолей поджелудочной железы
Celebre et al. Anaplastic meningioma with extensive single-cell infiltration: a potential role for epithelial-mesenchymal transformation in the progression of a meningothelial tumour?
KAFEEL et al. Lymphangioma of the ovary
WO2013102118A3 (en) Imageable patient tumors in mice
WO2012174529A3 (en) Methods for increasing the potency and efficacy of stem cells

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 20 SEP 2017 BY COMPUTER PACKAGES INC

Effective date: 20141118

LAPS Patent lapsed